CoChat
Sign Up
Cited by 146Cancer Risks and FactorsDiabetes, Cardiovascular Risks, and LipoproteinsMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Metabolic risk score and cancer risk: pooled analysis of seven cohorts

Open access
Stocks, Tanja, Bjørge, Tone, Ulmer, Hanno, Manjer, Jonas, Häggström, Christel, Nagel, Gabriele, Engeland, Anders, Johansen, Dorthe, Hallmans, Göran, Selmer, Randi, Concin, Hans, Tretli, Steinar, Jonsson, Håkan, Stattin, Pär·2015·International Journal of Epidemiology
DOI 10.1093/ije/dyv001PMC PMC4588859
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: There are few data on the joint influence of metabolic factors on risk of separate cancers. METHODS: We analysed data on body mass index, blood pressure and plasma levels of glucose, total cholesterol and triglycerides from seven European cohorts comprising 564 596 men and women with a mean age of 44 years. We weighted those factors equally into a standardized metabolic risk score [MRS, mean = 0, standard deviation (SD) = 1], with an individual's level indicated as SDs from the sex- and cohort-specific means. Cancer hazard ratios were calculated by Cox regression with age as timescale and with relevant adjustments including smoking status. All statistical tests were two-sided. RESULTS: During a mean follow-up of 12 years, 21 593 men and 14 348 women were diagnosed with cancer. MRS was linearly and positively associated with incident cancer in total and at sites (P < 0.05). In men, risk per SD MRS was increased by 43% (95% confidence interval: 27-61) for renal cell cancer, 43% (16-76) for liver cancer, 29% (20-38) for colon cancer, 27% (5-54) for oesophageal cancer, 20% (9-31) for rectal cancer, 19% (4-37) for leukaemias, 15% (1-30) for oral cancer and 10% (2-19) for bladder cancer. In women, risk increases per SD MRS were 56% (42-70) for endometrial cancer, 53% (29-81) for pancreatic cancer, 40% (16-67) for renal cell cancer, 27% (9-47) for cervical cancer and 17% (3-32) for rectal cancer. CONCLUSION: This largest study to date on the joint influence of metabolic factors on risk of separate cancers showed increased risks for several cancers, in particular renal cell and liver cancer in men and endometrial and pancreatic cancer in women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ije/dyv001

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Hazard ratio (HR, black line) and 95% confidence interval (shaded area) of cancer incidence (A) (n cases = 21 593) and cancer mortality (B) (n cases = 8572) in men, and cancer incidence (C) (n cases = 14 348) and cancer mortality (D) (n cases = 4405) in women, by the metabolic risk score (mean = 0, SD = 1). Models were derived from restricted cubic spline regression, with knots placed at percentiles 5, 35, 65 and 95. Attained age was used as timescale, and models were stratified by cohort and birth year and adjusted for baseline age and smoking status. HRs were corrected for a regression dilution ratio of 0.69 for metabolic risk score by exp(log(HR)/0.69). Participants with values more extreme than ± 3 SD were excluded from the analyses (n excluded ≤ 1845). P-value LR test, linear-spline, refers to likelihood-ratio tests of the linear model nested in a model with addition of splines.
Figure 1. Hazard ratio (HR, black line) and 95% confidence interval (shaded area) of cancer incidence (A) (n cases = 21 593) and cancer mortality (B) (n cases = 8572) in men, and cancer incidence (C) (n cases = 14 348) and cancer mortality (D) (n cases = 4405) in women, by the metabolic risk score (mean = 0, SD = 1). Models were derived from restricted cubic spline regression, with knots placed at percentiles 5, 35, 65 and 95. Attained age was used as timescale, and models were stratified by cohort and birth year and adjusted for baseline age and smoking status. HRs were corrected for a regression dilution ratio of 0.69 for metabolic risk score by exp(log(HR)/0.69). Participants with values more extreme than ± 3 SD were excluded from the analyses (n excluded ≤ 1845). P-value LR test, linear-spline, refers to likelihood-ratio tests of the linear model nested in a model with addition of splines.CC BY-NC · PubMed Central
Figure 2. Hazard ratio (HR) and 95% confidence interval of incident cancer at separate sites in men (A), women (B) and men and women combined (C) by the metabolic risk score (MRS, mean = 0, SD = 1). HRs were derived from Cox regression models with attained age as timescale, strata for cohort, birth year and sex and adjustment for baseline age and smoking status. HRs were corrected for a regression dilution ratio of 0.69 for metabolic risk score by exp(log(HR)/0.69). ICD-7 180.0 and 180.9 denoting renal cell cancer, and ICD-7172 denoting endometrial cancer, include a fraction of tumours that morphologically differ from the clinical classification of these cancers. HRs for cancer of the stomach, colon and pancreas differed significantly between men and women, so these cancers are not included in (C). Phet refers to P-value for heterogeneity between cohorts which was tested by likelihood ratio tests in which a model with the continuous metabolic risk score was compared with a model additionally including a product term of metabolic risk score and cohort.
Figure 2. Hazard ratio (HR) and 95% confidence interval of incident cancer at separate sites in men (A), women (B) and men and women combined (C) by the metabolic risk score (MRS, mean = 0, SD = 1). HRs were derived from Cox regression models with attained age as timescale, strata for cohort, birth year and sex and adjustment for baseline age and smoking status. HRs were corrected for a regression dilution ratio of 0.69 for metabolic risk score by exp(log(HR)/0.69). ICD-7 180.0 and 180.9 denoting renal cell cancer, and ICD-7172 denoting endometrial cancer, include a fraction of tumours that morphologically differ from the clinical classification of these cancers. HRs for cancer of the stomach, colon and pancreas differed significantly between men and women, so these cancers are not included in (C). Phet refers to P-value for heterogeneity between cohorts which was tested by likelihood ratio tests in which a model with the continuous metabolic risk score was compared with a model additionally including a product term of metabolic risk score and cohort.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

Sorted by citations

See all 146

Related

Metadata

Authors
Stocks, T., Bjørge, T., Ulmer, H., Manjer, J., Häggström, C., Nagel, G., Engeland, A., Johansen, D., Hallmans, G., Selmer, R., Concin, H., Tretli, S., Jonsson, H., & Stattin, P.
Affiliations
  • Lund University (SE)
  • Cancer Registry of Norway (NO)
  • Innsbruck Medical University (AT)
  • Umeå University (SE)
  • Universität Ulm (DE)
  • Norwegian Institute of Public Health (NO)
Corresponding author
Stocks, Tanja
ORCID
Venue
International Journal of Epidemiology
Publisher
Oxford University Press (OUP)
Published
2015-02-03
Volume
44
Issue
4
Pages
1353-1363
ISSN
  • 0300-5771 (ISSN-L)
  • 1464-3685
DOI
10.1093/ije/dyv001
PMC
PMC4588859
OpenAlex
W2132610504
Cited by
146
References
40
Citations by year
2026: 5 · 2025: 9 · 2024: 10 · 2023: 15 · 2022: 11 · 2021: 12 · 2020: 15 · 2019: 16 · 2018: 14 · 2017: 13 · 2016: 16 · 2015: 8
FWCI
7.42
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • International Journal of Epidemiology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by-nc)
  • BIBSYS Brage (BIBSYS (Norway)) (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion, other-oa)
Funders
  • Wereld Kanker Onderzoek Fonds
  • World Cancer Research Fund (2007/09)
  • Norwegian Institute of Public Health
Topics
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
metabolic risk score, cancer risk, body mass index, blood pressure, plasma glucose, total cholesterol, triglycerides, renal cell carcinoma, liver cancer, endometrial cancer, pancreatic cancer, colon cancer, esophageal cancer, rectal cancer, leukemia, oral cancer, bladder cancer, cervical cancer, sex differences
MeSH terms
Adult, Blood Glucose, Blood Pressure, Cholesterol, Europe, Female, Humans, Male, Middle Aged, Neoplasms, Risk Factors, Triglycerides, Cohort Studies, Body Mass Index, Proportional Hazards Models, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review